CoChat

Reconsidering Adjuvant Immunotherapy for Tuberculosis

Wallis, Robert S. · 2005 · Clinical Infectious Diseases

The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Shortened regimens for treatment of pulmonary tuberculosis (TB) are urgently needed to facilitate its global eradication. Prolonged treatment is presently required to prevent relapse, which is thought to arise from persisting foci of semidormant infection contained within granulomas. METHODS: The medical literature was reviewed to identify clinical trials of adjuvant TB immunotherapy, as well as other studies of the relationship between immune status and TB relapse or reactivation. RESULTS: Four studies of therapeutic interferon indicated its inability to effectively augment the mycobactericidal capacity of lung macrophages. One randomized, placebo-controlled trial of therapeutic interleukin-2 found that it delayed the microbiologic response to treatment, whereas 2 controlled trials of anti-tumor necrosis factor (TNF) therapies (high-dose prednisolone and etanercept [a soluble TNF receptor]) found that these interventions significantly accelerated the response to treatment. Four retrospective studies were identified in which the response to TB therapy was accelerated and/or the relapse risk was reduced in persons with human immunodeficiency virus coinfection; one study reported that immune reconstitution syndrome due to use of antiretroviral therapy was associated with increased risk of relapse. Several studies indicated that granulomas may be efficiently targeted and disrupted by the anti-TNF antibody infliximab, apparently because of its ability to bind to cell-surface TNF and to induce apoptosis in TNF-expressing cells. CONCLUSIONS: These findings support the hypothesis that the granulomatous host response to TB may paradoxically protect sequestered mycobacteria from administered anti-TB therapy and that treatment may be improved by therapeutic disruption of granulomas. Clinical trials to test this hypothesis are warranted.

Overview

Integrity signals

Registry

Crossref · 10.1086/430914

Cites

75 of 75 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Research works printed but not linked: 10

  1. O’Brien RJ, 2001, Global Alliance for TB Drug Development. Tuberculosis, 81, 1
  2. Giosue S, 2000, Eur Cytokine Netw, 11, 99
  3. InterMune investor relations press release: InterMune enrolls first patient in phase III trial in multidrug-resistant tuberculosis. 2000. Available at: http://www.hopkins-tb.org/news/7-31-2000.shtml. Accessed 18 May 2005.
  4. de Oliveira MM, 2004, Jornal Brasileiro Pneumologia, 30, 461
  5. East African-British Medical Research Councils, 1974, Lancet, 2, 237
  6. Bilaceroglu S, 1999, Int J Tuberc Lung Dis, 3, 47
  7. Dhillon J, 1989, Br J Exp Pathol, 70, 103
  8. Batten JC, 1957, Br J Exp Pathol, 38, 424
  9. Flynn JL, 2004, Tuberculosis. Philadelphia: Lippincott Williams & Wilkins, 237
  10. Joloba ML, 2000, Int J Tuberc Lung Dis, 4, 528

Cited by

See all 121

Metadata

Authors
Wallis, R. S.
Affiliations
Pharmaceutical Product Development (United States) (US)
Corresponding author
Wallis, Robert S.
Venue
Clinical Infectious Diseases
Published
2005-07-15
Volume
41
Issue
2
Pages
201-208
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W2133199321
Cited by
121
References
75
Citations by year
2026: 1 · 2025: 3 · 2024: 2 · 2023: 6 · 2022: 2 · 2021: 2 · 2020: 1 · 2019: 3 · 2018: 5 · 2017: 2 · 2016: 7 · 2015: 5 · 2014: 7 · 2013: 5 · 2012: 13
FWCI
1.29
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Infectious Diseases (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Amgen
  • Louisiana State University
Topics
  • Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
  • Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
  • Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
Keywords
pulmonary tuberculosis, adjuvant immunotherapy, tuberculosis relapse, granuloma, anti-TNF therapy, infliximab, etanercept, prednisolone, interleukin-2, interferon therapy, HIV coinfection, immune reconstitution inflammatory syndrome, antiretroviral therapy, tuberculosis treatment response
MeSH terms
Antitubercular Agents, Humans, Immunotherapy, Tuberculosis, Pulmonary, Drug Resistance, Multiple, Bacterial

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.